Charles Q. Morris - Jan 1, 2025 Form 3 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Chief Medical Officer
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Stock symbol
LVTX
Transactions as of
Jan 1, 2025
Transactions value $
$0
Form type
3
Date filed
1/2/2025, 09:21 AM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LVTX Share Options (Right to Buy) Jan 1, 2025 Common Shares 210K $3.86 Direct F1
holding LVTX Share Options (Right to Buy) Jan 1, 2025 Common Shares 160K $1.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 52,500 of the shares underlying the option vested on February 6, 2024 and the remainder vests in 36 equal monthly installments beginning on March 6, 2024, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F2 The shares underlying the option vest in 48 equal monthly installments beginning on February 19, 2024, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.